The next EEC meeting will take place at SIOPE during the European Bone Sarcoma Networking Meeting (EBSNM). EEC sessions will be held on the afternoon of Thursday 23 May 2019.
The full programme and information on the venue and accommodation can be found on the SIOP Europe website where you can also find out about the social events.
Agenda (pdf)
Thursday 23 May 2019
13:00-14:30 | Lunch |
14:30-14:40 | Introduction – Stefan Bielack and Jeremy Whelan |
Ìý | Session 1 Ewing sarcoma |
14:40-14:50 | Achievements of European collaboration in Ewing sarcoma – Jeremy Whelan |
14:50-15:05 | EUROEWING 2012 – Keith Wheatley |
15:05-15:20 | EWING 2008 – Uta Dirksen |
15:20-15:35 | Progress in recurrent and refractory disease – Martin McCabe |
15:35-15:50 | Introducing and testing new agents – Claudia Valverde |
15:50-16:00 | Discussion |
16:00-16:30 | Coffee break |
Ìý | Session 2 Current dilemmas |
16:30-16:50 | When is radiotherapy indicated for ES? - Beate Timmerman |
16:50-17:20 | Does computer navigation improve patient outcomes for pelvic and other resections? What are the implications for future care? - Michael Parry |
17:20-17:40 | How could ERNs affect the European bone sarcoma community - Ruth Ladenstein |
17:40-18:00 | Lessons from the COG Soft Tissue Sarcoma Committee regarding opportunities for international collaboration - Doug Hawkins |
Ìý | Discussion |
20:00 | Networking evening ArrostoÌýÌýÌý |
Friday 24 May 2019
08:30-10:30 ÌýÌý ÌýSession 3 Osteosarcoma
08:30-08:45 ÌýÌý ÌýEURAMOS-1: Past, present and future achievements of European collaboration in Osteosarcoma – Stefan Bielack
08:45-09:00 ÌýÌý ÌýWhat can a national programme of trials for osteosarcoma achieve? Nathalie Gaspar
09:00-09:15 ÌýÌý ÌýBRCAness revisited - Michaela Nathrath
09:15-09:30 ÌýÌý ÌýMolecular evolution of osteosarcoma through time – Daniel Baumhoer
09:30-09:45 ÌýÌý ÌýTreatment options beyond 1st line in osteosarcoma (recurrent non-resectable tumours) - Emanuela Palmerini
09:45-10:00 ÌýÌý ÌýWhy would countries like to join existing infrastructure and how could they do this? - Anna Raciborska
10:00-10:15 ÌýÌý ÌýICONIC – a national cohort study – Sandra Strauss
10:15-10:30 ÌýÌý ÌýDiscussion
10:30-11:00 ÌýÌý ÌýCoffee break
11:00-13:00 ÌýÌý ÌýSession 4 More Dilemmas and Challenges
11:00-11:15 ÌýÌý ÌýTargeting Metastasis in Ewing Sarcoma with T Cell Receptor Based Immunotherapy – Stefan Burdach
11:15-11:30 ÌýÌý ÌýEwing sarcoma as a second malignancy - Katja Kauertz
11:30-11:45 ÌýÌý ÌýWhere are we with tumours carrying BCOR-CCNB3 and CIC–DUX4 fusions? -Ìý Enrique d’Alava
11:45-12:00 ÌýÌý ÌýWhat does the bone sarcoma community require of the ITCC and vice versa? – Nathalie Gaspar
12:00 -12:30 ÌýÌý ÌýLessons from the past 10 years of COG Bone Tumor Committee Trials and Tribulations and Thoughts about the Future of International Collaboration - Katie Janeway
12:30-13:00 ÌýÌý Ìý
What studies can we do?
Bielack, Whelan, Janeway to lead discussion
13:00-14:00 ÌýÌý ÌýLunch
14:00-16:00 ÌýÌý ÌýCLOSED MEETING Bone Tumour Data Harmonization (agenda (pdf))
16:00-16:30 ÌýÌý ÌýCoffee break
16:30-18:00 ÌýÌý ÌýCLOSED MEETING Bone Tumour Data Harmonization